Details for Patent: 9,969,689
✉ Email this page to a colleague
Which drugs does patent 9,969,689 protect, and when does it expire?
Patent 9,969,689 protects WELIREG and is included in one NDA.
This patent has fifty-two patent family members in twenty-eight countries.
Summary for Patent: 9,969,689
| Title: | Aryl ethers and uses thereof |
| Abstract: | The present disclosure relates to HIF-2.alpha. inhibitors and methods of making and using them for treating cancer. Certain compounds were potent in HIF-2.alpha. scintillation proximity assay, luciferase assay, and VEGF ELISA assay, and led to tumor size reduction and regression in 786-O xenograft bearing mice in vivo. |
| Inventor(s): | Dixon; Darryl David (Somerset, NJ), Grina; Jonas (Coppell, TX), Josey; John A. (Dallas, TX), Rizzi; James P. (Irving, TX), Schlachter; Stephen T. (Dallas, TX), Wallace; Eli M. (Richardson, TX), Wang; Bin (Dallas, TX), Wehn; Paul (Dallas, TX), Xu; Rui (Dallas, TX), Yang; Hanbiao (Coppell, TX) |
| Assignee: | PELOTON THERAPEUTICS, INC. (Dallas, TX) |
| Application Number: | 15/439,308 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 9,969,689
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH VON HIPPEL-LINDAU DISEASE WHO REQUIRE THERAPY FOR ASSOCIATED RENAL CELL CARCINOMA, CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS, OR PANCREATIC NEUROENDOCRINE TUMORS, NOT REQUIRING IMMEDIATE SURGERY | ⤷ Try a Trial | ||
| Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | TREATMENT OF ADULT PATIENTS WITH ADVANCED RENAL CELL CARCINOMA FOLLOWING A PROGRAMMED DEATH RECEPTOR-1 OR PROGRAMMED DEATH-LIGAND INHIBITOR AND A VASCULAR ENDOTHELIAL GROWTH FACTOR TYROSINE KINASE INHIBITOR | ⤷ Try a Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,969,689
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 097600 | ⤷ Try a Trial | |||
| Australia | 2014318025 | ⤷ Try a Trial | |||
| Canada | 2919397 | ⤷ Try a Trial | |||
| China | 105530923 | ⤷ Try a Trial | |||
| China | 110372550 | ⤷ Try a Trial | |||
| Cuba | 20160030 | ⤷ Try a Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
